CJC-1295 + Ipamorelin 15mg — Vial Spec, Reconstitution Math & COA

Overview of the 15mg Vial Spec and Catalog Availability

The 15mg CJC-1295 + Ipamorelin vial is a high-mass lyophilized co-formulation optimized for research environments executing multi-subject in vitro assays or longitudinal animal studies. Combining a growth-hormone-releasing hormone (GHRH) analog with a selective growth hormone secretagogue receptor (GHSR-1a) agonist, this dual-peptide matrix eliminates the need to reconstitute separate single-agent vials, establishing identical molar or mass ratios per aliquot across extensive assay runs.

In standard analytical formulations, a 15mg blend contains a 1:1 mass ratio (7.5mg CJC-1295 No DAC and 7.5mg Ipamorelin), offering substantial working volume for automated liquid handling systems and high-density multi-well plates. While high-volume core labs frequently utilize the 15mg specification for large animal cohorts, PX1 Research primary stock maintains the standard CJC-1295 No DAC + Ipamorelin 10mg Blend for general research protocols, alongside custom batch fills for specialized high-volume orders across our complete catalog of research peptides.

Synergistic Mechanism: GHRH Analog and GHRP Secretagogue Co-Formulation

CJC-1295 (without DAC) functions as a synthetic 29-amino-acid peptide analog of endogenous GHRH (specifically modified at positions 2, 8, 15, and 27 to extend plasma half-life compared to native GHRH 1-29). Preclinical models demonstrate that CJC-1295 binds selectively to the GHRH receptor on anterior pituitary somatotrope cells, stimulating cyclic adenosine monophosphate (cAMP) accumulation and initiating endogenous growth hormone synthesis.

Ipamorelin, a pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2), operates via a parallel but distinct pathway as a selective agonist of the ghrelin/growth hormone secretagogue receptor (GHSR-1a). In vitro pituitary cell cultures reveal that Ipamorelin activation triggers intracellular calcium influx via protein kinase C pathways. When co-administered in preclinical studies, the simultaneous activation of GHRH and GHSR-1a receptors yields a synergistic surge in pulsatile growth hormone secretion far exceeding the additive sum of either peptide isolated. This dual action elevates downstream insulin-like growth factor 1 (IGF-1) expression, making the combination a primary candidate for tissue repair and cellular regeneration models.

Reconstitution Math & Concentration Calculations for 15mg Vials

Accurate reconstitution of a 15mg combined mass vial requires accounting for total active peptide content relative to diluent volume. Whether utilizing target mass concentrations or combined microgram yields, precise micropipetting relies on clear volumetric calculations. Researchers seeking automated verification can utilize our integrated reconstitution calculator for precise micro-volume planning.

Below are the standardized concentration metrics for a 15mg combined vial (assuming a standard 1:1 ratio of 7.5mg CJC-1295 No DAC and 7.5mg Ipamorelin) reconstituted with Bacteriostatic Water or Sterile Normal Saline:

1. Reconstitution with 1.0 mL Diluent: Yields a total peptide concentration of 15.0 mg/mL (15.0 µg/µL). Each 100 µL aliquot delivers 1.5 mg total mass (750 µg CJC-1295 / 750 µg Ipamorelin). This high concentration is ideal for micro-injection arrays or low-volume microfluidic systems.

2. Reconstitution with 2.0 mL Diluent: Yields a total peptide concentration of 7.5 mg/mL (7.5 µg/µL). Each 100 µL aliquot delivers 750 µg total mass (375 µg CJC-1295 / 375 µg Ipamorelin). This standard concentration optimizes volumetric accuracy for manual micropipettes.

3. Reconstitution with 3.0 mL Diluent: Yields a total peptide concentration of 5.0 mg/mL (5.0 µg/µL). Each 100 µL aliquot delivers 500 µg total mass (250 µg CJC-1295 / 250 µg Ipamorelin). This diluted concentration minimizes percent volumetric measurement error during serial dilution series.

Aliquoting Strategies and Stability Parameters for High-Throughput Assays

Working with 15mg high-mass vials introduces specific handling considerations to prevent peptide degradation over extended research timelines. Upon initial reconstitution with bacteriostatic water (containing 0.9% benzyl alcohol), the solution remains microbiologically stable under refrigeration (2°C to 8°C) for up to 28 days.

However, to mitigate repeated thermal fluctuations during daily sampling from a single 15mg vial, laboratory protocols recommend sub-aliquoting the reconstituted stock into low-binding polypropylene micro-centrifuge tubes. Freezing single-use working aliquots at -20°C extends functional stability for up to 90 days, provided the aliquots do not undergo multiple freeze-thaw cycles, which induce mechanical shear stress and peptide aggregation.

Quality Assurance: ISO 17025 HPLC/MS Purity & Endotoxin Testing

Dual-peptide co-lyophilization demands rigorous analytical verification to ensure that both sequence species remain fully distinct, unaggregated, and present at exact stoichiometric mass ratios. PX1 Research subjects every production lot to rigorous third-party testing in an ISO 17025 accredited laboratory.

Purity is verified using high-performance liquid chromatography (HPLC), ensuring a combined chemical purity of ≥98.0%. Mass identity for both CJC-1295 (MW: ~3367.9 g/mol) and Ipamorelin (MW: 711.86 g/mol) is confirmed independently via electrospray ionization mass spectrometry (ESI-MS). Furthermore, bacterial endotoxin testing via Chromogenic LAL assay guarantees endotoxin content remains strictly under <0.5 EU/mg, protecting sensitive in vitro cell cultures and animal models from confounding inflammatory responses. Every customer can view lot-matched analysis directly on our verified certificate of analysis portal.

Comparative Benchmarking: CJC-1295/Ipamorelin vs. Alternative Secretagogues

In secretagogue and growth factor research, selecting the appropriate axis-modulating compound depends on target receptor kinetics and desired half-life parameters. While the CJC-1295 No DAC + Ipamorelin combination provides clean, pulsatile GH release without significant cortisol or prolactin elevation, alternative compounds exhibit distinct operational profiles in preclinical studies.

For example, Sermorelin presents a shorter terminal elimination half-life (~11–12 minutes) compared to CJC-1295 No DAC (~30 minutes), requiring different sampling windows in pharmacokinetic research. First-generation GHRPs like GHRP-6 induce potent GH release but also trigger off-target stimulation of ghrelin-mediated appetite centers and mild cortisol release in rodent models. Conversely, long-acting single-agents such as CJC-1295 DAC incorporate a Drug Affinity Complex that covalently binds plasma albumin, sustaining systemic GHRH receptor activity over several days rather than the physiological pulsatile release targeted by short-acting blends.

Selecting Vial Mass: 5mg, 10mg, vs. 15mg High-Volume Assays

Determining whether to specify 5mg, 10mg, or 15mg vial configurations depends on experimental design, assay throughput, and reconstituted shelf-life constraints:

• 5mg Blends: Ideal for pilot studies, exploratory in vitro screens, or small rodent groups where reconstituted solution will be exhausted within 5–7 days, minimizing working solution decay.

• 10mg Blends: The industry standard for medium-scale preclinical trials. The PX1 standard CJC-1295 No DAC + Ipamorelin 10mg Blend balances cost-per-milligram efficiency with minimal reconstitution waste for typical 14-day study schedules.

• 15mg Blends: Preferred by high-throughput institutional laboratories conducting large-scale longitudinal animal trials or automated screening pipelines. 15mg vials yield lower unit costs per microgram when high daily usage volumes prevent reconstituted storage degradation. High-volume core facilities requiring bulk quantities can access scalable logistics through our wholesale lab portal.

Storage Protocols: Lyophilized Powder vs. Reconstituted Liquid Phase

Maintaining structural integrity across both CJC-1295 and Ipamorelin peptides requires adherence to strict physical storage parameters. In its lyophilized (powder) form, the 15mg blend matrix is stable at room temperature for up to 30 days during transit, but must be transferred to long-term cold storage upon receipt:

1. Long-Term Lyophilized Storage: Store vials sealed with desiccant at -20°C for up to 24 months, or at -80°C for extended archival stability up to 36 months.

2. Reconstituted Liquid Storage: Maintain at 2°C to 8°C under dark, refrigerated conditions. Avoid exposure to direct ultraviolet light, which can catalyze tryptophan photo-oxidation in the Ipamorelin peptide sequence. Detailed storage guidelines are indexed in the PX1 research knowledge base.

Preclinical Applications in Tissue Repair and IGF-1 Secretion Models

Preclinical investigations utilizing CJC-1295 and Ipamorelin co-administration focus primarily on downstream somatotropic axis activation. Rodent model studies indicate that dual secretagogue administration induces elevation of circulating IGF-1, a primary mediator of cellular proliferation, collagen synthesis, and extracellular matrix remodeling.

In vitro models evaluating musculoskeletal repair utilize these blends to quantify osteoblast differentiation, chondrocyte proliferation, and skeletal muscle satellite cell activation. By maintaining baseline pulsatile pituitary function without desensitizing GHRH or GHSR receptors, the CJC-1295 + Ipamorelin dual-agent model remains the benchmark standard for studying accelerated wound healing, bone density preservation, and systemic protein anabolism in preclinical laboratory settings.